Pfizer Pilots COVID-19 Immunization Plan In Four States As ‘Dry Run’

CEO Bourla Says Safety Data Support EUA Filing

Nov 17 2020

• By Jessica Merrill

Listen to this article

The company's Phase III COVID-19 vaccine trial has reached the needed safety data required for filing an emergency use authorization with the FDA, Bourla confirmed at the Stat Summit.

Child pilot aviator with airplane dreams of traveling in summer in nature at sunset — Pfizer is conducting a test run for its COVID-19 vaccine • Source: Shutterstock

Pfizer Inc. is launching a COVID-19 vaccine distribution pilot program in four states as the timeline for potentially delivering the first commercial vaccine to the public inches closer. During a presentation at the Stat Summit on 17 November, CEO Albert Bourla confirmed that the safety threshold required for its COVID-19 vaccine to be considered for an emergency use authorization by the US Food and Drug Administration has been reached.

He declined to confirm a filing timeline for the EUA but said it would be filed soon. Pfizer and its...

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain
Aug 22 2024
• By Alaric DeArment
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy
Aug 16 2024
• By Alaric DeArment
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
AstraZeneca Moves To Join Invyvid In COVID-19 Prevention
Jul 04 2024
• By Elizabeth Cairns
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
Stock Watch: Thoroughly Moderna Missteps
Jun 18 2024
• By Andy Smith
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings
Jun 17 2026
ghghghghghjhjhjhj